Abstract 19805: Characteristics and Disparity of Care Among Heart Failure Patients in the Midwest Participating in Get With the Guidelines-Heart Failure
Background: Heart failure places a burden on the healthcare system and affects African Americans (AA) disproportionately. AA have greater fatality rates, and prior to age 50, AA have a heart failure incidence rate 20 times higher than Caucasians. There are several predictive risk factors associated with heart failure incidence including hypertension, obesity, and diabetes, all of which are more common in the AA population. The same evidence-based treatment guidelines apply to both AA and Caucasians with heart failure, with the exception of the recommendation of hydralazine plus isosorbide dinitrate for AA. The objective of this study was to examine the quality of care and characteristics of AA heart failure patients compared to Caucasians.
Methods: There were 28642 heart failure patients analyzed from January 1 to December 31, 2015 from 11 Midwest states using Get With The Guidelines-Heart Failure (GWTG-HF). GWTG-HF is an in-hospital quality initiative that improves care by promoting adherence to scientific treatment guidelines in heart failure patients. Of the heart failure patients analyzed, 52% were male and 48% were female, while 18.8% were AA and 81.2% were Caucasian. Achievement and quality measures, characteristics, and defect-free care were examined.
Results: AA heart failure patients had a median age of 62, while Caucasian heart failure patients had a median age of 77. AA heart failure patients had a higher prevalence of diabetes and hypertension. Overall, AA and Caucasians had similar quality of care, though AA were more likely to receive an aldosterone antagonist at discharge and DVT prophylaxis during hospitalization. For both AA and Caucasians, defect free care was provided 82.1% of the time.
Conclusions: AA and Caucasian heart failure patients receive similar quality of care but differed in age, DVT prophylaxis and use of an aldosterone antagonist. Further research should examine the causes of these differences of aldosterone use and DVT prophylaxis.
Author Disclosures: C. Dickens: None. K. Thomas: None.
- © 2016 by American Heart Association, Inc.